Results 41 to 50 of about 1,258,688 (288)
Comparison of Ki-67 equivalent antibodies [PDF]
Journal of Clinical Pathology, 2002 To compare commercially available Ki-67 equivalent antibodies with regard to qualitative and quantitative immunohistochemical staining characteristics.The following antibodies were used: monoclonal MIB-1 (Immunotech), monoclonal MM1 (Novocastra), polyclonal NCL-Ki-67p (Novocastra), and polyclonal Rah Ki-67 (Dako).
C F, Lindboe, S H, Torp
openaire +2 more sources
Expression of Ki 67 and P53 immunohistochemical markers in central nervous system astrocytoma
مجلة كلية الطب, 2015 Background: Astrocytic tumors are the most common primary tumors of the central nervous system. Several grading systems are used to grade astrocytomas.
Mahmood Sh. Mahmood +1 more
doaj +1 more source
Diagnostic Pathology, 2022 Background Ki-67 standard reference card (SRC) and artificial intelligence (AI) software were used to evaluate breast cancer Ki-67LI. We established training and validation sets and studied the repeatability inter-observers.
Lina Li +4 more
doaj +1 more source
A cytohistological study of Ki-67 expression in ovarian tumors
Indian Journal of Pathology and Microbiology, 2011 Background and Objective: The study was conducted to evaluate the diagnostic accuracy of imprint cytology in ovarian neoplasms, and to investigate the biological significance of Ki-67 antigen expression in benign and malignant ovarian tumors and ...
Monisha Choudhury +2 more
doaj +1 more source
Automated assessment of Ki‐67 proliferation index in neuroendocrine tumors by deep learning
Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS), 2021 The Ki‐67 proliferation index (PI) is a prognostic factor in neuroendocrine tumors (NETs) and defines tumor grade. Analysis of Ki‐67 PI requires calculation of Ki‐67‐positive and Ki‐67‐negative tumor cells, which is highly subjective.
T. Vesterinen +5 more
semanticscholar +1 more source
Breast Cancer, 2021 Introduction Breast cancer is a heterogeneous disease. Our study focuses on a monoinstitutional series of patients affected by Hormone Responsive carcinomas (luminal A and luminal B) and aims to define an optimal Ki-67 cut-off, to correctly stratify ...
A. Lombardi +4 more
semanticscholar +1 more source
Expression of ki-67 and p53 in meningiomas
Neoplasma, 2013 Meningiomas account for about 30% of all primary brain tumors. It is difficult to predict the behaviour of meningiomas, and identification of protein markers responsible for the regulation of cell proliferation can be very helpful. The aim of this study was to evaluate immunohistochemical expression of Ki-67 and p53 in 170 meningiomas.A total number of
Pogorelić, Zenon +6 more
openaire +5 more sources
Immunoexpression of Ki-67 and endoglin corroborating hamartomatous nature of sialoangiolipoma
Contemporary Clinical Dentistry, 2017 Mesenchymal neoplasms of salivary gland including adipocytes are relatively uncommon entity classified as monophasic and biphasic. Sialolipoma, a biphasic mesenchymal salivary gland neoplasm, with a prominent vascularity designated as sialoangiolipoma ...
Swagatika Panda +4 more
doaj +1 more source
Journal of Translational Medicine, 2023 Background and purpose Ki-67 labeling index (LI) is an important indicator of tumor cell proliferation in glioma, which can only be obtained by postoperative biopsy at present.
Ningfang Du +10 more
doaj +1 more source
Thoracic Cancer, 2019 Background The Ki‐67 labeling index (LI) is a well‐known prognostic factor for primary breast cancer, but its clinical significance for metachronous axillary lymph node (ALN) recurrence has not been well documented.
Naoya Ishibashi +7 more
doaj +1 more source